RE:News Release Issued: Mar 15, 2017 (5:00am MDT)GV, so the good news continues to roll in and it addresses the point I made at the end of a previous post re apabetalone and Crestor (and right from the horses mouth and what a surprise). I am still surprised that we have not seen anything from Astra-Zenica (Crestor) regarding Resverlogix. I guess they still will make lots of money from Crestor on it's own.
Bear posted a link on Agora going right back to the ASSURE trial. https://www.resverlogix.com/media/press-release.html?id=492#.WMlHlxLyu7q
This is absolutely worth a thorough and slow read!
It seems like it was the fact that rvx-208 did not enhance the Lipitor group hence the overall average PAV regression for the combined Crestor and Lipitor patients was not statistically significant. HOWEVER, if you read the results of the combined Crestor (rosuvastatin) + rvx-208 (apabetalone) the results are highly statistically significant on many of the key measures.
It is no wonder that Eastern, NGN, CV Investments, etc did not pull the plug.
On the Zenith side there is the potential that we may see some valuable news on April 3 regarding results from the zen3694 trial on mCRPC patients. While this is entirely independent of apabetalone and MACE it could be another victory for the credibility of the RVX and Zenith epigenetic approaches and their proprietary scaffolds used to build their compounds.
As critical as I have been of Don over the years he and Dr Wong are steering a couple of ships in a very positive direction IMHO. Keep it happening.
What I am most pleasantly surprised about is the rapidity of new positive findings regarding apabetalone and it seem like starting a couple of years ago they started utilizing very powerful chemical analysis systems plus the big data approach of Emerald Logics system to analyse thousands of chemical interactions.
So what a great announcement re the patent today. Go to the link and read that 2013 press release!!!
GLTA
Toinv